170 related articles for article (PubMed ID: 23688265)
41. Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone.
Tavecchia L; Masera N; Russo P; Cirò A; Vincenzi A; Vimercati C; Masera G
Haematologica; 2006 Jun; 91(6 Suppl):ECR19. PubMed ID: 16785138
[TBL] [Abstract][Full Text] [Related]
42. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
[TBL] [Abstract][Full Text] [Related]
43. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.
Evans P; Kayyali R; Hider RC; Eccleston J; Porter JB
Transl Res; 2010 Aug; 156(2):55-67. PubMed ID: 20627190
[TBL] [Abstract][Full Text] [Related]
44. On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure.
Pennell DJ; Carpenter JP; Roughton M; Cabantchik Z
J Cardiovasc Magn Reson; 2011 Sep; 13(1):45. PubMed ID: 21910880
[TBL] [Abstract][Full Text] [Related]
45. Intermediate-term evaluation of a pratical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac t2*.
Ha SY; Mok AS; Chu WC; Rasalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
Hemoglobin; 2011; 35(3):199-205. PubMed ID: 21599432
[TBL] [Abstract][Full Text] [Related]
46. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
Kolnagou A; Kontoghiorghe CN; Kontoghiorghes GJ
Drug Res (Stuttg); 2017 Jul; 67(7):404-411. PubMed ID: 28320041
[TBL] [Abstract][Full Text] [Related]
47. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
[TBL] [Abstract][Full Text] [Related]
48. Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study.
Ricchi P; Ammirabile M; Spasiano A; Costantini S; Cinque P; Di Matola T; Pagano L; Prossomariti L
Eur J Haematol; 2010 Jul; 85(1):36-42. PubMed ID: 20331740
[TBL] [Abstract][Full Text] [Related]
49. Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with beta-thalassaemia major: comparison between different chelation regimens.
Christoforidis A; Haritandi A; Tsatra I; Tsitourides I; Karyda S; Athanassiou-Metaxa M
Eur J Haematol; 2007 Jan; 78(1):52-7. PubMed ID: 17042760
[TBL] [Abstract][Full Text] [Related]
50. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
Kolnagou A; Kleanthous M; Kontoghiorghes GJ
Eur J Haematol; 2010 Nov; 85(5):430-8. PubMed ID: 20662901
[TBL] [Abstract][Full Text] [Related]
51. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
Kontoghiorghes GJ; Kolnagou A
Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
[TBL] [Abstract][Full Text] [Related]
52. Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit.
Ladis V; Chouliaras G; Berdoukas V; Moraitis P; Zannikos K; Berdoussi E; Kattamis C
Eur J Haematol; 2010 Oct; 85(4):335-44. PubMed ID: 20561034
[TBL] [Abstract][Full Text] [Related]
53. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
[TBL] [Abstract][Full Text] [Related]
54. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial.
Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Romeo MA; Magnano C; Caruso V; Argento C; Gerardi C; Campisi S; Violi P; Malizia R; Cianciulli P; Rizzo M; D'Ascola DG; Quota A; Prossomariti L; Fidone C; Rigano P; Pepe A; D'Amico G; Morabito A; Gluud C
Br J Haematol; 2009 Apr; 145(2):245-54. PubMed ID: 19236376
[TBL] [Abstract][Full Text] [Related]
55. Reversal of heart failure in thalassemia major by combined chelation therapy: a case report.
Tsironi M; Deftereos S; Andriopoulos P; Farmakis D; Meletis J; Aessopos A
Eur J Haematol; 2005 Jan; 74(1):84-5. PubMed ID: 15613114
[TBL] [Abstract][Full Text] [Related]
56. Maintenance of normal range body iron store levels for up to 4.5 years in thalassemia major patients using deferiprone monotherapy.
Kolnagou A; Kontoghiorghes GJ
Hemoglobin; 2010 Jun; 34(3):204-9. PubMed ID: 20524810
[TBL] [Abstract][Full Text] [Related]
57. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major.
Farmaki K; Angelopoulos N; Anagnostopoulos G; Gotsis E; Rombopoulos G; Tolis G
Br J Haematol; 2006 Aug; 134(4):438-44. PubMed ID: 16822284
[TBL] [Abstract][Full Text] [Related]
58. Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major.
Waheed N; Ali S; Butt MA
J Ayub Med Coll Abbottabad; 2014; 26(3):297-300. PubMed ID: 25671931
[TBL] [Abstract][Full Text] [Related]
59. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study.
Berdoukas V; Chouliaras G; Moraitis P; Zannikos K; Berdoussi E; Ladis V
J Cardiovasc Magn Reson; 2009 Jun; 11(1):20. PubMed ID: 19558722
[TBL] [Abstract][Full Text] [Related]
60. Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients.
Hatzipantelis ES; Karasmanis K; Perifanis V; Vlachaki E; Tziomalos K; Economou M
Hemoglobin; 2014; 38(2):111-4. PubMed ID: 24351163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
